Associate Professor, Medicine, USC School of Medicine
Hematology
Dr. Anil Tulpule, MD
|
|
Give Review
Anil Tulpule practices Hematology. Anil Tulpule is also published. He has 22 publications published. The lastest publication: "p53 Expression Is a Strong Marker of Inferior Survival in De Novo Diffuse Large B-Cell Lymphoma and May Have Enhanced Negative Effect With MYC Coexpression: A Single I...' He accepts all Medicare patients.
Publications
- p53 Expression Is a Strong Marker of Inferior Survival in De Novo Diffuse Large B-Cell Lymphoma and May Have Enhanced Negative Effect With MYC Coexpression: A Single I...
- Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047.
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and a...
- Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliati...
- Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma.
- KSHV-induced notch components render endothelial and mural cell characteristics and cell survival.
- Bendamustine therapy in chronic lymphocytic leukemia.
- Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
- Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.
- Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymp...
- Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical ef...
- Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy.
- Multidrug resistance in AIDS-related lymphoma.
- AIDS-related Burkitt''s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in ...
- Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretrovir...
- Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium.
- Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hod...
- Treatment of AIDS related non-Hodgkin's lymphoma with combination mitoguazone dihydrochloride and low dose CHOP chemotherapy: results of a phase II study.
- Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma.
- Characteristics of indolent non-Hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection.
- Multidrug resistance (MDR-1) expression in AIDS-related lymphomas.
Doctors Specialties
- Family Medicine
- Hematology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Pathway X Tiered Direct Access
- Select PPO
- Access Plus Savenet
- Basic Exclusive PPO for Small Business
- Basic PPO
- Great West Healthcare-Cigna PPO
- Commercial Insurance Company
- Covered California - Bronze PPO
- Health Net PPO
- Individual and Family PPO
- Medicare Advantage PFFS
- Medicare MCR
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Drug Facts
| NPI NUMBER | 1710913249 | |
| NPPES Provider LastName | TULPULE | |
| NPPES Provider FirstName | ANIL | |
| NPPES Provider ZIPCode | 900890112 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology | |
| Total Claim Count | 36.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1710913249 |
| Last Name Of The Provider | TULPULE |
| First Name Of The Provider | ANIL |
| View All |
Similar Doctors
|
|
Dr. Gary L. Buchschacher Jr., MD |
|
Dr. Joel Jaffe, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Salima Multani, MD |
|
|
Dr. Clan K. Hahn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard S. Finn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan Claster, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary C. Territo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Doris E. Lyonga, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kevin J. McDonnell, MD |
|
|
Dr. Sarmen V. Sarkissian, MD |
|
|
Dr. James Y. Shen, MD |
|
|
Preet M. Chaudhary, MB
This Doctor is OpenDoctor Recommended.
|
|
|
H Schlossberg |